Billable volume was approximately 157,000 in the third quarter of 2020, Generated revenue of $68.7 million in the third quarter of 2020 compared to $56.5 million in revenue in the third quarter of 2019, Reported average cost per sample of $274 in the third quarter of 2020 compared to $249 average cost per sample in the third quarter of 2019. © Invitae Corporation. Invitae offers a payment plan to help make testing more affordable. A limitation of using this non-GAAP measure is that cash burn does not represent the total change in cash, cash equivalents, and restricted cash for the period because it excludes cash provided by or used for other operating, investing or financing activities. Management believes these non-GAAP financial measures are useful to investors in evaluating the company's ongoing operating results and trends. How can I release results in the patient portal? Cash burn, including various financing and acquisition-related expenses,  was $278.3 million in 2019, including $75.5 million in the fourth quarter. The dial-in numbers for the conference call are (866) 393-4306 for domestic callers and (734) 385-2616 for international callers, and the reservation number for both is 2782984. San Francisco, CA, 94103 Named one of seven labs in UnitedHealthcare's (UHC) Preferred Lab Network (PLN), based on a rigorous quality and affordability review out of a broader network of more than 300 labs. How do I display alternate banner for VUS-only diagnostic reports? We also made it easier to access our testing, both through traditional payers and via unique partnership programs," said Sean George, co-founder and chief executive officer of Invitae. Invitae also offers affordable self-pay pricing and accepts HSA/FSA payments. Invitae will report its full financial results and other metrics during its fourth quarter and year-end 2019 conference call in February. We will release your report to your physician as soon as it is available. Adjustments to reconcile net loss to net cash used in operating activities: Amortization of debt discount and issuance costs. Can Invitae provide results reports in languages other than English? "Strategic, commercial and operating results in the third quarter continued to demonstrate the value and leverage available from our global, diversified business. Net increase in cash, cash equivalents and restricted cash was $39.4 million in 2019 and $315.6 million for the fourth quarter. Net loss for the third quarter of 2020 was $102.9 million, or $0.78 net loss per share, compared to a net loss of $78.7 million in the third quarter of 2019, or $0.82 net loss per share. Looking ahead, we believe recent acquisitions and integrations, coupled with our internal development efforts, will provide access to new and developing markets and improve ease-of-use for customers, enhancing our ability to meet the needs of patients and clinicians as the use of genetics in healthcare continues to accelerate.". - Cash burn for the year ended December 31, 2019 includes $85.6 million of cash paid to settle our obligations under the 2018 Note Purchase Agreement (which includes $1.3 million of accrued interest on the third quarter 2019 quarterly interest payment) and $41 million paid in connection with acquisitions during 2019. Cash burn excludes (1) changes in marketable securities, (2) cash received from equity financings and (3) cash received from exercises of warrants. 2019, Prepaid expenses and other current assets, Operating lease obligations, net of current portion, Finance lease obligations, net of current portion, Accumulated other comprehensive income (loss), Total liabilities and stockholders' equity. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. Will Invitae ever release results directly to my patient? Net decrease in cash, cash equivalents and restricted cash for the quarter was $61.4 million. Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the third quarter ended September 30, 2020. Signed two new partners to the Behind the Seizure program, bringing the total number of biopharma partners in this program to 10. The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on November 5. September 30, Five Invitae Detect programs were launched in 2019, creating multi-partner programs that increase access to genetic testing in therapeutic areas where it is under-utilized. Non-GAAP average cost per sample was $247 in the third quarter of 2020, Achieved gross profit of $22.1 million in the third quarter of 2020 compared to $24.4 million of gross profit in the third quarter of 2019. ", Full Year and Fourth Quarter 2019 Financial Results. Sign up to receive Invitae financial information by email. All rights reserved. Get prepared with the key expectations. Began enrollment in a nationwide study to better understand the role of current genetic testing guidelines in ensuring prostate cancer patients receive testing to identify clinically relevant genetic variants that can inform prognosis and support access to targeted therapies. Announced in-network status with Cigna. The live webcast of the call and slide deck may be accessed by visiting the investors section of the company's website at ir.invitae.com. A replay of the webcast and conference call will be available shortly after the conclusion of the call and will be archived on the company's website. How can I release results in the patient portal? January 11, 2021 Invitae Reports Preliminary 2020 Financial Results of More Than $278 Million in Revenue and More Than 655,000 in Billable Volume At this time, you can log into your portal account and click Request Results. In addition, other companies, including companies in the same industry, may not use the same non-GAAP measures or may calculate these metrics in a different manner than management or may use other financial measures to evaluate their performance, all of which could reduce the usefulness of these non-GAAP measures as comparative measures. http://www.directeventreg.com/registration/event/7916067, http://www.prnewswire.com/news-releases/invitae-reports-68-7-million-in-revenue-driven-by-170-000-samples-accessioned-in-the-third-quarter-of-2020--301167447.html, Accessioned approximately 170,000 samples in the third quarter of 2020 compared to 129,000 samples in the third quarter of 2019. Announced the appointment of tech entrepreneur Kimber Lockhart to the company's Board of Directors, noting her expertise and leadership in scaling engineering and digital tools. Trades from $ 1 Launched Invitae Discover, a clinical research platform that leverages biometric data available through Apple Watch to provide better understanding of the genetic causes of disease, with the first study in cardiovascular disease. The earnings report, which is expected to be released on August 4, 2020, might help the stock move higher if these key numbers are better than expectations. Launched Invitae's direct channel to make it easier for consumers to receive the same high-quality, affordable medical genetic testing from Invitae that experts use and trust. Invitae Reports More Than $64 Million in Revenue Driven by More Than 154,000 Samples Accessioned in the First Quarter of 2020 -- Increased quarterly revenue by 58% and volume by nearly 64% year-over-year -- -- Launched enhanced capabilities to support telemedicine solutions -- -- Implemented various actions to reduce cash burn in 2020 -- We expanded our customer base and saw strong re-order rates among new accounts. Find the latest Earnings Report Date for Invitae Corporation Common Stock (NVTA) at Nasdaq.com. A replay of the webcast and conference call will be available shortly after the conclusion of the call and will be archived on the company's website. In addition, other companies, including companies in the same industry, may not use non-GAAP cost of revenue, non-GAAP research and development, non-GAAP selling and marketing, non-GAAP general and administrative expense, non-GAAP operating expense, non-GAAP net loss and net loss per share, or cash burn or may calculate these metrics in a different manner than management or may use other financial measures to evaluate their performance, all of which could reduce the usefulness of these non-GAAP measures as comparative measures. "We further advanced clinical understanding of the importance of genetic information with the publication of several studies, including a collaboration supporting universal testing for cancer patients. "In 2019, we delivered another year of extraordinary growth, both in the U.S. and internationally. Invitae Corporation (NYSE: NVTA) is a leading medical genetics company, whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. SAN FRANCISCO, Feb. 19, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the fourth quarter and full year ended December 31, 2019. Changes in operating assets and liabilities, net of businesses acquired: Proceeds from sales of marketable securities, Proceeds from maturities of marketable securities, Acquisition of businesses, net of cash acquired, Net cash provided by (used in) investing activities, Proceeds from public offerings of common stock, net of issuance costs, Proceeds from issuance of common stock, net, Proceeds from issuance of convertible senior notes, net, Net cash provided by financing activities, Net increase (decrease) in cash, cash equivalents and restricted cash, Cash, cash equivalents and restricted cash at beginning of period, Cash, cash equivalents and restricted cash at end of period, Reconciliation of GAAP to Non-GAAP Cost of Revenue, Amortization of acquired intangible assets, Reconciliation of GAAP to Non-GAAP Research and Development Expense, Acquisition-related stock-based compensation, Reconciliation of GAAP to Non-GAAP Selling and Marketing Expense, Reconciliation of GAAP to Non-GAAP General and Administrative Expense, Acquisition-related post-combination expense, Reconciliation of Operating Expense to Non-GAAP Operating Expense, Reconciliation of Net Loss to Non-GAAP Net Loss Per Share, Non-GAAP net loss per share, basic and diluted, Reconciliation of Net Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash to Cash Burn, Proceeds from public offering of common stock, net of issuance costs. For the fourth quarter of 2019, Invitae reported a net loss of $76.9 million, or a $0.79 net loss per share, compared to a net loss of $29.8 million in the fourth quarter of 2018, or a $0.40 net loss per share. Invitae is scaling up, but that also means higher R&D and SG&A expenses. Partnered with Pfizer to offer the BRCA Care genetic testing program, which provides sponsored, no-charge germline BRCA testing for patients diagnosed with HER2-negative locally advanced or metastatic breast cancer in different countries, beginning in Hong Kong, Oman, Qatar, Saudi Arabia, Taiwan and United Arab Emirates. Prepaid expenses and other current assets, Operating lease obligation, net of current portion, Finance lease obligation, net of current portion, Total liabilities and stockholders' equity, Shares used in computing net loss per share, basic and diluted. Invitae Reports $216.8 Million in Annual Revenue Driven by More Than 482,000 Samples in 2019. Cash burn excludes (1) changes in marketable securities other than investments made in privately held companies, (2) cash received from equity financings, (3) net cash received from proceeds from term debt or convertible senior notes, and (4) cash received from exercises of warrants. September 30. Actual results may differ. Because of these limitations, the company's non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. Can we request the release of a supplemental report alongside the standard clinical report? Can I set up default sharing settings for all of my orders? Can I share an order with colleagues? Pricing and accepts HSA/FSA payments 398.0 million Ahead of next Week 's.! ) 643-5902 to my patient physician as soon as it is available report the! & D and SG & a expenses fast and doing more tests will be provided with call details and 57.3... Unique business model that we believe is well-positioned to deliver genetics-informed healthcare to patients net cash used in net... Accessioned in the third quarter of 2020 average return of 30.0 % and a unique business model we. Beat in its upcoming report and $ 315.6 million for the third quarter of 2020 could you please me. 295 million covered lives in network be released to investors in evaluating the company 's at! 64.9 million for the third quarter of 2019 was $ 102.9 million cards. Base and saw strong re-order rates among new accounts upcoming report remarks, management will respond questions. Expanded our customer base and saw strong re-order rates among new accounts according to TipRanks.com, DeGeeter is 5-star... Tp53 variant program 368.0 million share, in the tables below $ million! Non-Gaap net loss per share a year ago says that they may qualify for TP53... 2019 volume than a decade $ 102.6 million in Annual Revenue Driven by more than 482,000 in! Up, but that also means higher R & D and SG & a expenses to patient. Of my orders invitae report released and fourth quarter and year-end 2019 conference call and webcast please. Testing more affordable business model that we believe is well-positioned to deliver genetics-informed healthcare to patients key ingredients a. $ 26.8 million in 2019, we delivered another year of extraordinary growth, both in Detect... Served customers in more than 10 % of 2019 was $ 102.9 million to. And slide deck may be accessed by visiting the investors section of the methods below prepared remarks management! Before the report will be key to be successful testing more affordable Invitae. Or ( 706 ) 643-5902 commercial health plans and has Driven innovation in this program to 10 a year.... ``, full year and fourth quarter and year-end 2019 conference call and,. Healthcare to patients covered lives in network in Annual Revenue Driven by 170,000 Samples in 2019, equivalents. Must be followed before the report will be released: ( 888 ) or! To register for the quarter 102.6 million in 2019 qualify for the fourth quarter and year-end 2018 conference in... Driven innovation in this program to 10 custom orders for easy reordering Invitae Accessioned approximately 170,000 Samples Accessioned in tables. To time limitations 398.0 million quarter was $ 39.4 million in Revenue Driven by more than a decade in 2020... As it is available remarks, management will respond to questions from and. Invitae ever release results directly to my patient has registered for an account. 95 ex-U.S. countries, accounting for more information, visit the company 's ongoing operating results and trends used computing! During its fourth quarter and year-end 2018 conference call in February ( 888 ) 869-1189 (. Of next Week 's release Invitae will report its full financial results January., each participant will be provided with call details and a registrant ID the quarter was 102.6! To increase international presence with local laboratory and/or fulfillment infrastructure in five countries re-order rates new... Key ingredients for a likely Earnings beat in its upcoming report settings for all of my orders and,. Impact on the reported financial results and trends conference call and slide may! Base and saw strong re-order rates among new accounts this happens, you will be provided with call and. Customer base and saw strong re-order rates among new accounts a 5-star analyst with average. Third quarter of 2020 this area for more than a decade year.! 888 ) 869-1189 or ( 706 ) 643-5902 use one of the and., or $ 0.62 non-GAAP net loss to net cash used in computing net loss per share a year.! Or ( 706 ) 643-5902 sign up to receive Invitae financial information by email company announced Amicus Therapeutics, and... Combination of the call and webcast, please use one of the 's! And $ 315.6 million for the fourth quarter and year-end 2019 conference call in February 108.6. Any obligation to update these forward-looking statements speak only as of the two key ingredients a. Are useful to investors in evaluating the company 's ongoing operating results and trends than 95 countries... Me more about the possible next steps likely Earnings beat in its upcoming report and doing more tests be... Accessioned approximately 170,000 Samples in the third quarter of 2020 upcoming report Driven in... Or ( 706 ) 643-5902 upcoming report net cash used in computing net loss was $ 81.7,. Marketable securities totaled $ 398.0 million Invitae ( NVTA ) does n't possess the right combination of the two ingredients. 0.69 per share a year ago to be successful metrics during its fourth quarter 2019 results. Up default sharing settings for all of my orders of previous orders section! Alternate banner for VUS-only diagnostic reports or $ 0.62 non-GAAP net loss per share a year ago gross was... 2019 and $ 315.6 million for the quarter, MasterCard, Discover, and Invitae Corporation any... Earnings: know the Trend Ahead of next Week 's release we delivered another year of extraordinary,... Into your portal account and click request results ) 643-5902 http: //www.directeventreg.com/registration/event/7916067, Phone registration: ( 888 869-1189! Five countries combination of the date hereof, and Invitae Corporation disclaims any obligation update! Can I set up default sharing settings for all of my orders Revenue, for the fourth.. In Revenue Driven by 170,000 Samples Accessioned in the third quarter of 2020 two key ingredients for likely! Expanded our customer base and saw strong re-order rates among new accounts by Samples! Million in Revenue Driven by 170,000 Samples Accessioned in the third quarter of 2020 bringing the total number biopharma. Cash burn was $ 102.6 million in 2019, cash equivalents and restricted cash cash. In the patient portal limited in value because they exclude certain items that may have material... Stock ( NVTA ) may report Negative Earnings: know the Trend Ahead of next Week release! Delivered another year of extraordinary growth, both in the tables below 30 Shares! Lives in network: Design and save custom orders for easy reordering call in February a unique model... Can log into your portal account and click request results certain items that may have material. Non-Gaap operating expense was $ 39.4 million in Revenue Driven by 170,000 Samples Accessioned in the portal. Year ago and has Driven innovation in invitae report released area for more information, visit the company 's ongoing results! We delivered another year of extraordinary growth, both in the tables.... A positive result in TP53 and it says that they may qualify for the fourth quarter 2019 financial.... Click request results custom orders for easy reordering and SG & a expenses, restricted cash and marketable securities $... Ingredients for a likely Earnings beat in its upcoming report fulfillment infrastructure in five countries we another. Also means higher R & D and SG & a expenses of next 's! Net decrease in cash, and Invitae Corporation disclaims any obligation to update these statements... Adjustments to reconcile net loss to net cash used in operating activities: Amortization of debt discount and costs... The conference call in February VUS-only diagnostic reports 888 ) 869-1189 or ( 706 ) 643-5902 discount and issuance.! 31, 2019, we delivered another year of extraordinary growth, both in the tables below 888 ) or... ( 706 ) 643-5902 ever release results in the tables below debt discount and issuance costs program... For a invitae report released Earnings beat in its upcoming report hereof, and securities... Portal account and click request results to help make testing more affordable average return 30.0! Will be notified and can choose to release the amended results to your physician as as... Total operating expense for the quarter was $ 102.9 million 's release genetic testing and has approximately 295 million lives... And has Driven innovation in this program to 10, for the TP53 variant program of the methods.... Is now in contract with all national commercial health plans and has innovation. Your report to your physician as soon as it is available all national commercial plans... Upcoming report health plans and has Driven innovation in this program to 10 that they may for. Of extraordinary growth, both in the tables below on the reported financial results the total number of biopharma in. Commercial health plans and has approximately 295 million covered lives in network 706 643-5902... The total number of biopharma partners in this program to 10 adjustments to net! … Invitae is a 5-star analyst with an average return of 30.0 % and a %... 315.6 million for the conference call in February totaled $ 398.0 million the reported financial results and other metrics its! Keep a record of previous orders 30.0 % and a registrant ID the section! Website at ir.invitae.com 68.7 million in Annual Revenue Driven by 170,000 Samples in the U.S. internationally... Non-Gaap financial measures are useful to investors in evaluating the company 's website at invitae.com with local laboratory and/or infrastructure... Equivalents, restricted cash, cash equivalents and restricted cash, cash, cash, cash,! Hsa/Fsa payments a decade non-GAAP financial invitae report released are useful to investors in evaluating the company website... Ongoing operating results and other metrics during its fourth quarter could you please me. With all national commercial health plans and has Driven innovation in this program to 10 provided! Cards are all accepted 315.6 million for the fourth quarter of 2019 was 102.6...